Recombinant Anti-BAFF x Anti-B7RP1 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-BAFF and anti-B7RP1 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can bind and inactivate two ligands simultaneously. It can inhibit B cell survival and T cell costimulation. It is designed for the research of Systemic lupus erythematosus (SLE) therapy.